FDA panel recommends BMS's belatacept for kidney transplant rejection
02 March 2010
Daniel B. Moskowitz
By a 13-to-5 vote, the US
FDA's advisory committee on cardiovascular and renal drugs on March 1st recommended that the agency grant
Bristol-Myers Squibb's biologics licence application for belatacept, to be used to prevent rejection of transplanted kidneys.
The agency most often follows the...
Please Login to read the full article.
02 March 2010
Daniel B. Moskowitz
The agency most often follows the...
Please Login to read the full article.
RELATED CONTENT
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
